Dutasteride and active surveillance of low-risk prostate cancer

The Lancet

Volumn 379, Issue 9826, 2012, Pages 1590-

  Fleshner, Neil E ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

DUTASTERIDE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE INHIBITOR;

CANCER EPIDEMIOLOGY; CANCER HORMONE THERAPY; CANCER RISK; LETTER; PRIORITY JOURNAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK ASSESSMENT; URINARY TRACT DISEASE;

5-ALPHA REDUCTASE INHIBITORS; AZASTEROIDS; FEMALE; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 84860265669     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(12)60678-3     Document Type: Letter

References (5)

1. Parker C. What (if anything) to do about low-risk prostate cancer. Lancet 2012; 378: 1078-80.
2. Fleshner NE, Lucia MS, Egerdie B, et al. Dutasteride in localised prostate cancer management: the REDEEM randomised, double-blind, placebo-controlled trial. Lancet 2012; 378: 1103-11.
3. Barocas DA, Cowan JE, Smith JA Jr, Carroll PR. What percentage of patients with newly diagnosed carcinoma of the prostate are candidates for surveillance? An analysis of the CaPSURE database. J Urol 2008; 180: 1330-34.
4. Andriole GL, Bostwick DG, Brawley OW, et al. Effect of dutasteride on the risk of prostate cancer. N Engl J Med 2010; 362: 1192-202.
5. Thompson IM, Chi C, Ankerst DP, et al. Effect of fi nasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst 2006; 98: 1128-33.